...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>World Journal of Gastroenterology >Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma.
【24h】

Re-evaluation of antitumor effects of combination chemotherapy with interferon-alpha and 5-fluorouracil for advanced hepatocellular carcinoma.

机译：干扰素-α和5-氟尿嘧啶联合化疗对晚期肝细胞癌的抗肿瘤作用的重新评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To evaluate the efficacy of combination chemotherapy with interferon-alpha (IFNalpha) and 5-fluorouracil (5-FU) in patients with advanced hepatocellular carcinoma (HCC). METHODS: Twenty-eight HCC patients in advanced stage were enrolled in the study. They were treated with IFNalpha/5-FU combination chemotherapy. One cycle of therapy lasted for 4 wk. IFNalpha (3X10(6) units) was subcutaneously injected thrice weekly on days 1, 3, and 5 for 3 wk, and 5-FU (500 mg/d) was administered via the proper hepatic artery for 5 consecutive days per week for 3 wk. No drugs were administered during the 4(th) wk. The effect of combination chemotherapy was evaluated in each patient after every cycle based on the reduction of tumor volume. RESULTS: After the 1(st) cycle of therapy, 16 patients showed a partial response (PR, 57.1%) but none showed a complete response (CR, 0%). At the end of therapy, the number of patients who showed a CR, PR, or no response (NR) was 1, 10, and 17, respectively. The response rate for therapy (CR+PR) was 21.5%. Biochemical tests before therapy were compared between responsive (CR+PR) and non-responsive (NR) patients, but no significant differences were found for any of the parameters examined, indicating that no reasonable predictors could be identified in our analysis. CONCLUSION: Attempts should be made to discriminate between responders and non-responders by evaluating tumor size after the first cycle of IFNalpha/5-FU combination chemotherapy. For non-responders, therapy should not proceed to the next cycle, and instead, different combination of anticancer drugs should be explored.
机译：目的：评估干扰素-α（IFNalpha）和5-氟尿嘧啶（5-FU）联合化疗对晚期肝细胞癌（HCC）患者的疗效。方法：28例晚期肝癌患者被纳入研究。他们接受了IFNalpha / 5-FU联合化疗。一个疗程持续了4周。在第1、3和5天每周三次皮下注射IFNalpha（3X10（6）单位），连续3周，每周3次，通过适当的肝动脉给予5-FU（500 mg / d），连续3天周。在第4周期间未给药。在每个周期后，根据肿瘤体积的减少来评估每例患者联合化疗的效果。结果：在第一个疗程后，有16例患者显示出部分缓解（PR，57.1％），但没有患者显示出完全缓解（CR，0％）。在治疗结束时，显示CR，PR或无反应（NR）的患者人数分别为1、10和17。治疗的缓解率（CR + PR）为21.5％。比较了有反应的（CR + PR）和无反应的（NR）患者在治疗前的生化测试，但是在所检查的任何参数上均未发现显着差异，这表明在我们的分析中无法确定合理的预测指标。结论：应尝试通过评估IFNα/ 5-FU联合化疗第一周期后的肿瘤大小来区分反应者和非反应者。对于无反应者，治疗不应进入下一个周期，而应探索不同的抗癌药物组合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号